ArticlePediatric blood & cancer2017

Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.

Jodi R Mayfield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.